Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity

被引：5

作者：

Pittman, Phillip R. ^{[1
]}

Fisher, Diana ^{[2
]}

Quinn, Xiaofei ^{[2
]}

Schmader, Trevor ^{[2
]}

Barrera-Oro, Julio G. ^{[2
]}

机构：

[1] US Army Med Res Infect Dis USAMRIID, Dept Clin Res, Ft Detrick, MD USA

[2] USAMRIID, Keaki Tech LLC, Ft Detrick, MD USA

来源：

VACCINE | 2013年 / 31卷 / 44期

关键词：

AVA; BioThrax (R) anthrax vaccine adsorbed; Human antibody response to anthrax; vaccine; INHALATIONAL ANTHRAX; SAFETY; EFFICACY; IMMUNOGENICITY;

D O I：

10.1016/j.vaccine.2013.08.086

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We describe the Bacillus anthracis protective antigen IgG antibody response and the B. anthracis lethal toxin neutralization activity to a delayed dose of anthrax vaccine adsorbed (AVA, BioThrax (R)) using validated assays. 373 individuals received 1, 2, or 3 priming doses, 18-24 months afterward, they received a delayed dose of AVA. Overall, 23.6% of subjects showed detectable anti-PA IgG before the boost, compared to 99.2% (P< 0.0001) 28 days after the boost. Geometric mean anti-PA IgG concentration (GMC) was 1.66 mu g/mL before and 887.82 mu g/mL after the boost (P< 0.0001). The proportion of individuals with four-fold increase in GMC following the boost ranged from 93.8% to 100%. Robust anti-PA IgG levels and B. anthracis lethal toxin neutralization activity are induced when an AVA dose is delayed as long as two years. These data support continuing with the vaccination schedule when a dose is delayed as long as two years rather than restarting the series. Published by Elsevier Ltd.

引用

页码：5009 / 5014

页数：6

共 22 条

[1]

[Anonymous], 1978, ANTHR VACC ADS

[2] Fatal inhalational anthrax in a 94-year-old Connecticut woman [J].

Barakat, LA ;

Quentzel, HL ;

Jernigan, JA ;

Kirschke, DL ;

Griffith, K ;

Spear, SM ;

Kelley, K ;

Barden, D ;

Mayo, D ;

Stephens, DS ;

Popovic, T ;

Marston, C ;

Zaki, SR ;

Guarner, J ;

Shieh, WJ ;

Carver, HW ;

Meyer, RF ;

Swerdlow, DL ;

Mast, EE ;

Hadler, JL .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (07) :863-868

[3] FIELD-EVALUATION OF A HUMAN ANTHRAX VACCINE [J].

BRACHMAN, PS ;

FEKETY, FR ;

GOLD, H ;

WERRIN, M ;

INGRAHAM, NR ;

PLOTKIN, SA .

AMERICAN JOURNAL OF PUBLIC HEALTH AND THE NATIONS HEALTH, 1962, 52 (04) :632-+

[4]

*COMM ASS SAF EFF, 2002, ANTHR VACC IS IT SAF

[5]

Emergent BioSolutions, 2012, BIOTHRAX ANTHR VACC

[6] Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin [J].

Fellows, PF ;

Linscott, MK ;

Ivins, BE ;

Pitt, MLM ;

Rossi, CA ;

Gibbs, PH ;

Friedlander, AM .

VACCINE, 2001, 19 (23-24) :3241-3247

[7]

Fowler R. A., 2011, Journal of Bioterrorism and Biodefense, V2, P107

[8] Anthrax vaccine - Evidence for safety and efficacy against inhalational anthrax [J].

Friedlander, AM ;

Pittman, PR ;

Parker, GW .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (22) :2104-2106

[9]

Friedlander AM, 2000, CURR CLIN TOPICS INF, V20, P335

[10] Validation of the anthrax lethal toxin neutralization assay [J].

Hering, D ;

Thompson, W ;

Hewetson, J ;

Little, S ;

Norris, S ;

Pace-Templeton, J .

BIOLOGICALS, 2004, 32 (01) :17-27

← 1 2 3 →